In this article, we will discuss Durvalumab (Warnings-3). So, let’s get started.
Early identification and management of immune-mediated adverse reactions are essential to ensure safe
use of PD-1/PD-L1 blocking antibodies. Monitor patients closely for symptoms and signs that may be clinical manifestations of underlying immune-mediated adverse reactions. Evaluate liver enzymes,
creatinine, and thyroid function at baseline and periodically during treatment.